Eli Lilly and Co. and Innovent Biologics Inc. expanded their drug development collaboration to support the development and potential commercialization of up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, both inside and outside of China.
The Ontario Institute for Cancer Research and Novera Therapeutics Inc. will collaborate with Janssen Biotech, a pharmaceutical company of Johnson & Johnson, to develop small molecule drug candidates for hematological cancers.
Genentech and Arvinas Inc. entered into a license agreement for the development of new therapeutics using Arvinas' PROTAC technology. The multi-year strategic license agreement encompasses multiple disease targets.
The European Medicines Agency granted an Orphan Drug Designation to ENMD-2076, developed by CASI Pharmaceuticals Inc., for the treatment of hepatocellular carcinoma, including fibrolamellar carcinoma, a rare type of HCC.
MedImmune joined the Human Vaccines Project, a public-private partnership seeking to develop new vaccines and immunotherapies.
FDA approved Opdivo (nivolumab) to treat patients with non-squamous, advanced non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
FDA granted orphan drug designation to drug candidate BLU-554 for the treatment of hepatocellular carcinoma.
Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer.
Merck and Bionomics Limited extended their strategic collaboration for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.
FDA granted a Breakthrough Therapy designation to abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive advanced or metastatic breast cancer.
